Cancer Vaccines Drug Pipeline Market Report

Cancer Vaccines Drug Pipeline Market Analysis, Market Size, Application Analysis, Regional Outlook, Competitive Strategies And Forecasts, 2015 To 2022

Format: PDF  |  Report ID: GVR2883

The global cancer vaccine drug pipeline market is estimated to grow at a CAGR exceeding 27% from 2015 to 2022. Rising vaccines usage combined with other therapies is expected to drive market growth over the forecast period. Growing occurrence of different types of cancer and the introduction of new vaccines is anticipated to raise product demand over the next seven years.

Factors such as increasing number of cancer patients coupled with rising awareness towards benefits of vaccines, is expected to steer industry growth over the foreseeable future. Growing global geriatric population along with increasing disposable income in emerging economies are also anticipated to drive industry penetration in the region.

Increased usage of tobacco products, and alcohol consumption along with unhealthy diet and lack of physical activity are the main cancer risk factors prevalent worldwide. According to a post by WHO, Cancer is a leading cause for global deaths and is expected to rise by about 70% over the next two decades. Prostrate, cervical, lung, and breast cancers are common forms with less diagnostic and therapeutic techniques commercialized for the treatment.

Growing survival rate among cancer patients through a combination of vaccines with pharmacotherapeutics is anticipated to raise advanced cancer drugs demand over the next seven years.Dendritic cells are taken from a patient's immune system and then treated with chemicalsbefore being injected back into the patient through vaccines. These cells enhance immune response against the antibody cells and stimulate the other cells in the immune system to fight the cancerous cells.

Presence of promising late-stage pipeline drugs along with continuous development of potent drugs and increasing R&D spending of key pharmaceutical companies may be attributed to commercializing various medications promoting cancer vaccine drug pipeline market growth. For instance,Merck & Co. Ltd. employsrobust late stage pipeline technology in order to successfully launch new products into the market to address the major unmet medical needs.

Vendors in the industry have come up with various consumer favorableinitiatives such as patient-assistance programs through which the patients are provided with free or reduced cost branded medications to those who could not afford them. Medication affordability depends on various factors such as economic downturn, increase in drug prices or a growing market for expensive drugs.

The number of vaccine patients in clinical trials worldwide is expected to double over the next seven years owing to a variety of factors such as annual recurrence, prevalence, pandemic potential, resistant bacterial strains and epidemic. Growth in vaccine R&D is driven by new technologies,vaccines targeting unmet medical needs and increased health care spending in the developing world.

Sensitivity and complexity of cold chain management is expected to pose a major challenge tocancer vaccine drug pipelineindustry over the next few years. These vaccines are thermo-sensitive and needto be stored safely and distributed within an efficient cold-storage chain. To ensure the quality of the cold-chain all the firms assess the logistics and conditions of cold-chain systems. The companies also undertake training workshops to manage vaccine stock and monitoring storage procedures.

The cost of developing new drugs is enormously high typically costing hundreds of millions and is expected to reach 1 billion dollars over 15 years.  Considering the risk and thereby filtering out drugs that do not have growth in the market and may not eventually get approved is essential to the pharmaceutical industry to avoid additional cost to the firms.

The cancer vaccine drug pipeline product commercialization consists of four stages including discovery, pre-clinical, clinical trials and marketing (or post-approval). Pharmaceutical companies usually have a number of compounds in their pipelines. The drugs follow each and every stage and then are introduced in the market. The pipeline consists of the drugs in the development stage or testing stage and these includes a new variant and application of existing drugs.

Cancer vaccines have been segmented on the basis of product into therapeutic and prophylactic vaccine. Prophylactic market is expected to witness high growth over the forecast period as it prevents cancer from developing in the human body in the initial stages.Therapeutic vaccineindustry is anticipated to witness substantial growth over the next seven years owing to rising number of cancer patients and long known viability of these products.The drug value assessment process includes the size of potential market, market share the drug is expected to gain, the Food and drug administration (FDA) approval risk.

Vaccines contribute a minor share of total revenue in cancer treatment, however, the drug pipeline is anticipated to witness high growth over the forecast period. This is mainly because less number of products are acknowledged in the market after the final testing and also decreased sales from the approved products in economies of Central Africa and South East Asia.

Germany, the U.S. and Japan represent the largest markets for cancer vaccine manufacturers. Countries such as India, China and Thailand are expected to witness the highest growth in next seven years owing to increasing healthcare spending and consumer awareness.

Major players operating in the global cancer vaccine drug pipeline industry include Eisai Co. Ltd, F. Hoffmann-La Roche Ltd, Arbor Pharmaceuticals LLC, Bristol-Myers Squibb Co, and Merck & Co. Ltd. There is a high competition among global players. Companies have been adoptingvarious strategies such as product innovation or licensing technology platforms for vaccine development or alternative routes toward vaccine administration.

Key questions answered by the report
Request for Customization

Choose License Type:

Single User - $4,950
Multi User - $7,950
Enterprise User - $9,950

Special Pricing & Discounts

Avail customized purchase options to meet your research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert. Request for a free product review before report purchase.

  • Custom research service

    Custom research service

    Speak to the report author to design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service excellence represented in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • BOA